{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,23]],"date-time":"2026-01-23T09:33:37Z","timestamp":1769160817945,"version":"3.49.0"},"reference-count":127,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Current Research in Translational Medicine"],"published-print":{"date-parts":[[2023,4]]},"DOI":"10.1016\/j.retram.2023.103390","type":"journal-article","created":{"date-parts":[[2023,4,5]],"date-time":"2023-04-05T23:25:59Z","timestamp":1680737159000},"page":"103390","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Are we there yet? cellular therapies for cutaneous T cell lymphoma"],"prefix":"10.1016","volume":"71","author":[{"given":"Pinar Ataca","family":"Atilla","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8613-2105","authenticated-orcid":false,"given":"Erden","family":"Atilla","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.retram.2023.103390_bib0001","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1182\/blood-2018-11-881268","article-title":"The 2018 update of the WHO-EORTC classification for primary cutaneous lymphomas","volume":"133","author":"Willemze","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.retram.2023.103390_bib0002","doi-asserted-by":"crossref","DOI":"10.1007\/s40257-022-00749-1","article-title":"Development of Cutaneous T-Cell Lymphoma Following Biologic Treatment: A Systematic Review","author":"Schaefer","year":"2023","journal-title":"Am J Clin Dermatol"},{"issue":"1","key":"10.1016\/j.retram.2023.103390_bib0003","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1007\/s00428-022-03421-5","article-title":"Recent advances in cutaneous lymphoma-implications for current and future classifications","volume":"482","author":"Goodland","year":"2023","journal-title":"Virchows Arch"},{"issue":"18","key":"10.1016\/j.retram.2023.103390_bib0004","doi-asserted-by":"crossref","first-page":"5051","DOI":"10.1158\/1078-0432.CCR-12-0604","article-title":"Long-term outcomes of 1,263 patients with mycosis fungoides and S\u00e9zary syndrome from 1982 to 2009","volume":"18","author":"Talpur","year":"2012","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.retram.2023.103390_bib0005","doi-asserted-by":"crossref","first-page":"4730","DOI":"10.1200\/JCO.2009.27.7665","article-title":"Survival outcomes and prognostic factors in mycosis fungoides\/S\u00e9zary syndrome: validation of the revised International Society for Cutaneous Lymphomas\/European Organisation for Research and Treatment of Cancer staging proposal","volume":"28","author":"Agar","year":"2010","journal-title":"J Clin Oncol"},{"issue":"32","key":"10.1016\/j.retram.2023.103390_bib0006","doi-asserted-by":"crossref","first-page":"3766","DOI":"10.1200\/JCO.2015.61.7142","article-title":"Cutaneous Lymphoma International Consortium Study of Outcome in Advanced Stages of Mycosis Fungoides and S\u00e9zary Syndrome: Effect of Specific Prognostic Markers on Survival and Development of a Prognostic Model","volume":"33","author":"Scarisbrick","year":"2015","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.retram.2023.103390_bib0007","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1080\/10428194.2017.1347650","article-title":"Current systemic therapeutic options for advanced mycosis fungoides and S\u00e9zary syndrome","volume":"59","author":"Janiga","year":"2018","journal-title":"Leuk Lymphoma"},{"issue":"1","key":"10.1016\/j.retram.2023.103390_bib0008","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1182\/blood-2014-07-588236","article-title":"Lack of durable disease control with chemotherapy for mycosis fungoides and S\u00e9zary syndrome: a comparative study of systemic therapy","volume":"125","author":"Hughes","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.retram.2023.103390_bib0009","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1016\/S0140-6736(17)31266-7","article-title":"Brentuximab vedotin or physician's choice in CD30-positive cutaneous T-cell lymphoma (ALCANZA): an international, open-label, randomised, phase 3, multicentre trial","volume":"390","author":"Prince","year":"2017","journal-title":"Lancet"},{"issue":"9","key":"10.1016\/j.retram.2023.103390_bib0010","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1016\/S1470-2045(18)30379-6","article-title":"Mogamulizumab versus vorinostat in previously treated cutaneous T-cell lymphoma (MAVORIC): an international, open-label, randomised, controlled phase 3 trial","volume":"19","author":"Kim","year":"2018","journal-title":"Lancet Oncol"},{"issue":"56","key":"10.1016\/j.retram.2023.103390_bib0011","doi-asserted-by":"crossref","first-page":"95981","DOI":"10.18632\/oncotarget.21619","article-title":"Analysis of CTCL cell lines reveals important differences between mycosis fungoides\/S\u00e9zary syndrome vs. HTLV-1+ leukemic cell lines","volume":"8","author":"Netchiporouk","year":"2017","journal-title":"Oncotarget"},{"issue":"4","key":"10.1016\/j.retram.2023.103390_bib0012","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1002\/cncr.27740","article-title":"Hydrochlorothiazide and cutaneous T cell lymphoma: prospective analysis and case series","volume":"119","author":"Jahan-Tigh","year":"2013","journal-title":"Cancer"},{"issue":"3","key":"10.1016\/j.retram.2023.103390_bib0013","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1111\/1523-1747.ep12363352","article-title":"HLA-DR5 and DQB1*03 class II alleles are associated with cutaneous T-cell lymphoma","volume":"107","author":"Jackow","year":"1996","journal-title":"J Invest Dermatol"},{"issue":"22","key":"10.1016\/j.retram.2023.103390_bib0014","doi-asserted-by":"crossref","first-page":"3330","DOI":"10.1182\/blood-2014-09-598995","article-title":"KIR3DL2 is a coinhibitory receptor on Sezary syndrome malignant T cells that promotes resistance to activation-induced cell death","volume":"124","author":"Thonnart","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.retram.2023.103390_bib0015","first-page":"514","article-title":"New Insights into the complex mutational landscape of Sezary syndrome","volume":"10","author":"Mirza","year":"2020","journal-title":"FrontOncol"},{"key":"10.1016\/j.retram.2023.103390_bib0016","first-page":"2024","article-title":"MicroRNA signa-tures in diagnosis and prognosis of cutaneous T-cell lymphoma","volume":"138","author":"Shen","year":"2018","journal-title":"J InvestDermatol"},{"issue":"3","key":"10.1016\/j.retram.2023.103390_bib0017","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1182\/bloodadvances.2021005991","article-title":"Single-cell analysis of S\u00e9zary syndrome reveals novel markers and shifting gene profiles associated with treatment","volume":"7","author":"Borcherding","year":"2023","journal-title":"Blood Adv"},{"issue":"7","key":"10.1016\/j.retram.2023.103390_bib0018","doi-asserted-by":"crossref","first-page":"3538","DOI":"10.3390\/ijms23073538","article-title":"Epigenetics of Cutaneous T-Cell Lymphomas","volume":"23","author":"Hara","year":"2022","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.retram.2023.103390_bib0019","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1007\/s12253-015-9897-8","article-title":"Altered MicroRNA Expression in Folliculotropic and Transformed Mycosis Fungoides","volume":"21","author":"Marosv\u00e1ri","year":"2015","journal-title":"Pathol. Oncol. Res."},{"key":"10.1016\/j.retram.2023.103390_bib0020","doi-asserted-by":"crossref","first-page":"14667","DOI":"10.1007\/s13277-016-5325-2","article-title":"Aberrant microRNA expression in tumor mycosis fungoides","volume":"37","author":"Papadavid","year":"2016","journal-title":"Tumor Biol"},{"issue":"5","key":"10.1016\/j.retram.2023.103390_bib0021","doi-asserted-by":"crossref","first-page":"1520","DOI":"10.1038\/jid.2011.481","article-title":"Deep-Sequencing Analysis Reveals that the miR-199a2\/214 Cluster within DNM3os Represents the Vast Majority of Aberrantly Expressed MicroRNAs in S\u00e9zary Syndrome","volume":"132","author":"Qin","year":"2012","journal-title":"Journal of Investigative Dermatology"},{"issue":"1","key":"10.1016\/j.retram.2023.103390_bib0022","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1182\/blood.2019004256","article-title":"Genetic and epigenetic insights into cutaneous T-cell lymphoma","volume":"139","author":"Tensen","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.retram.2023.103390_bib0023","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1182\/blood-2009-11-251926","article-title":"Sezary syndrome and mycosis fungoides arise from distinct T-cell subsets: a biologic rationale for their distinct clinical behaviors","volume":"116","author":"Campbell","year":"2010","journal-title":"Blood.c"},{"key":"10.1016\/j.retram.2023.103390_bib0024","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.1182\/blood.2019002516","article-title":"Skin colonization by circulating neoplastic clones in cutaneous T-cell lymphoma","volume":"134","author":"Iyer","year":"2019","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.retram.2023.103390_bib0025","doi-asserted-by":"crossref","first-page":"2610","DOI":"10.1158\/1078-0432.CCR-21-4437","article-title":"Single-Cell RNA Sequencing Unveils the Clonal and Transcriptional Landscape of Cutaneous T-Cell Lymphomas","volume":"28","author":"Gaydosik","year":"2022","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.retram.2023.103390_bib0026","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.666935","article-title":"Singlecell RNA sequencing reveals tissue compartment-specific plasticity of mycosis fungoides tumor cells","volume":"12","author":"Rindler","year":"2021","journal-title":"Front Immunol"},{"issue":"1","key":"10.1016\/j.retram.2023.103390_bib0027","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.1038\/s41467-022-28799-3","article-title":"Single-cell transcriptomics links malignant T cells to the tumor immune landscape in cutaneous T cell lymphoma","volume":"13","author":"Liu","year":"2022","journal-title":"Nat Commun"},{"issue":"5","key":"10.1016\/j.retram.2023.103390_bib0028","first-page":"3037","article-title":"Immune signatures of CD4 and CD68 predicts disease progression in cutaneous T cell lymphoma","volume":"14","author":"Huang","year":"2022","journal-title":"Am J Transl Res"},{"key":"10.1016\/j.retram.2023.103390_bib0029","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1007\/s12185-017-2245-x","article-title":"Allogeneic hematopoietic stem cell transplantation for refractory mycosis fungoides (MF) and Sezary syndrome (SS)","volume":"106","author":"Atilla","year":"2017","journal-title":"Int J Hematol"},{"issue":"21","key":"10.1016\/j.retram.2023.103390_bib0030","doi-asserted-by":"crossref","first-page":"3331","DOI":"10.4161\/15384101.2014.965061","article-title":"Deregulation in STAT signaling is important for cutaneous T-cell lymphoma (CTCL) pathogenesis and cancer progression","volume":"13","author":"Netchiporouk","year":"2014","journal-title":"Cell Cycle"},{"issue":"3","key":"10.1016\/j.retram.2023.103390_bib0031","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1046\/j.0022-202x.2001.01436.x","article-title":"Constitutive and interleukin-7- and interleukin-15-stimulated DNA binding of STAT and novel factors in cutaneous T cell lymphoma cells","volume":"117","author":"Qin","year":"2001","journal-title":"J Invest Dermatol"},{"issue":"14","key":"10.1016\/j.retram.2023.103390_bib0032","doi-asserted-by":"crossref","first-page":"2172","DOI":"10.4161\/cc.25550","article-title":"Connecting the dots in cutaneous T cell lymphoma (CTCL): STAT5 regulates malignant T cell proliferation via miR-155","volume":"12","author":"Litvinov","year":"2013","journal-title":"Cell Cycle"},{"key":"10.1016\/j.retram.2023.103390_bib0033","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1016\/S1470-2045(19)30320-1","article-title":"IPH4102, a first-in-class anti-KIR3DL2 monoclonal antibody, inpatients with relapsed or refractory cutaneous T-cell lymphoma: an inter-national, first-in-human, open-label, phase 1 trial","volume":"20","author":"Bagot","year":"2019","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.retram.2023.103390_bib0034","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.1182\/blood-2011-08-376319","article-title":"Prognostic factors intransformed mycosis fungoides: a retrospective analysis of 100 cases","volume":"119","author":"Benner","year":"2012","journal-title":"Blood"},{"issue":"15","key":"10.1016\/j.retram.2023.103390_bib0035","doi-asserted-by":"crossref","first-page":"1818","DOI":"10.1182\/bloodadvances.2018020388","article-title":"Highly cytotoxic natural killer cells are associated with poor prognosis in patients with cutaneous T-cell lymphoma","volume":"2","author":"Mundy-Bosse","year":"2018","journal-title":"Blood Adv"},{"key":"10.1016\/j.retram.2023.103390_bib0036","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1038\/sj.bmt.1705741","article-title":"Graft versus lymphoma effect after early relapse following reduced-intensity sibling allogeneic stem cell transplantation for relapsed cytotoxic variant of mycosis fungoides","volume":"40","author":"Gabriel","year":"2007","journal-title":"Bone Marrow Transpl"},{"key":"10.1016\/j.retram.2023.103390_bib0037","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1016\/j.bbmt.2009.04.017","article-title":"A meta-analysis of patients receiving allogeneic or autologous hematopoietic stem cell transplant in mycosis fungoides and Sezary syndrome","volume":"15","author":"Wu","year":"2009","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.retram.2023.103390_bib0038","unstructured":"NCCN Guidelines on Mycosis Fungoides\/S\u00e9zary Syndrome [Internet]. 2020, Available online: https:\/\/www.nccn.org\/professionals\/physician_gls\/default_nojava.aspx#site"},{"key":"10.1016\/j.retram.2023.103390_bib0039","doi-asserted-by":"crossref","first-page":"3766","DOI":"10.1200\/JCO.2015.61.7142","article-title":"Cutaneous Lymphoma International Consortium Study of Outcome in Advanced Stages of Mycosis Fungoides and Sezary Syndrome: Effect of Specific Prognostic Markers on Survival and Development of a Prognostic Model","volume":"33","author":"Scarisbrick","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.retram.2023.103390_bib0040","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.1038\/s41409-022-01713-7","article-title":"Allogeneic transplantation in Cutaneous T-cell Lymphoma: improved outcomes associated with early transplantation and acute graft versus host disease","volume":"57","author":"Angelov","year":"2022","journal-title":"Bone Marrow Transplant"},{"issue":"6","key":"10.1016\/j.retram.2023.103390_bib0041","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1038\/s41409-020-01197-3","article-title":"Allogeneic hematopoietic stem cell transplantation for advanced mycosis fungoides and S\u00e9zary syndrome. An updated experience of the Lymphoma Working Party of the European Society for Blood and Marrow Transplantation","volume":"56","author":"Domingo-Domenech","year":"2021","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.retram.2023.103390_bib0042","doi-asserted-by":"crossref","first-page":"4492","DOI":"10.1200\/JCO.2010.29.3241","article-title":"Allogeneic hematopoietic cell transplantation for patients with mycosis fungoides and S\u00e9zary syndrome: a retrospective analysis of the lymphoma working party of the European group for blood and marrow transplantation","volume":"28","author":"Duarte","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.retram.2023.103390_bib0043","doi-asserted-by":"crossref","first-page":"3347","DOI":"10.1200\/JCO.2014.57.5597","article-title":"Long-term outcome of allogeneic hematopoietic cell transplantation for patients with mycosis fungoides and S\u00e9zary syndrome: a European society for blood and marrow transplantation lymphoma working party extended analysis","author":"Duarte","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.retram.2023.103390_bib0044","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.bbmt.2019.08.019","article-title":"Efficacy of allogeneic hematopoietic cell transplantation in cutaneous T cell lymphoma: results of a systematic review and metaanalysis","volume":"26","author":"Iqbal","year":"2020","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.retram.2023.103390_bib0045","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1038\/bmt.2014.161","article-title":"Allogeneic hematopoietic cell transplantation for mycosis fungoides and Sezary syndrome","volume":"49","author":"Lechowicz","year":"2014","journal-title":"Bone Marrow Transpl"},{"key":"10.1016\/j.retram.2023.103390_bib0046","doi-asserted-by":"crossref","first-page":"527","DOI":"10.3324\/haematol.2013.098145","article-title":"Allogeneic stem cell transplantation for advanced cutaneous T-cell lymphomas: a study from the French Society of Bone Marrow Transplantation and French Study Group on Cutaneous Lymphomas","volume":"99","author":"de Masson","year":"2014","journal-title":"Haematologica"},{"key":"10.1016\/j.retram.2023.103390_bib0047","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1002\/hon.2719","article-title":"Outcome of allogeneic hematopoietic stem cell transplantation for mycosis fungoides and S\u00e9zary syndrome","volume":"38","author":"Mori","year":"2020","journal-title":"Hematol Oncol"},{"key":"10.1016\/j.retram.2023.103390_bib0048","doi-asserted-by":"crossref","first-page":"2490","DOI":"10.1093\/annonc\/mdv473","article-title":"Allogeneic stem-cell transplantation in patients with cutaneous lymphoma: updated results from a single institution","volume":"26","author":"Hosing","year":"2015","journal-title":"Ann Oncol"},{"issue":"18","key":"10.1016\/j.retram.2023.103390_bib0049","doi-asserted-by":"crossref","first-page":"4474","DOI":"10.1182\/bloodadvances.2020001627","article-title":"Nonmyeloablative allogeneic transplantation achieves clinical and molecular remission in cutaneous T-cell lymphoma","volume":"4","author":"Weng","year":"2020","journal-title":"Blood Adv"},{"issue":"16_suppl","key":"10.1016\/j.retram.2023.103390_bib0050","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2022.40.16_suppl.e19045","article-title":"Mismatched donor transplantation with post-transplantation cyclophosphamide for advanced cutaneous T-cell lymphoma:A single-center experience","volume":"40","author":"Hughes","year":"2022","journal-title":"Journal of Clinical Oncology"},{"key":"10.1016\/j.retram.2023.103390_bib0051","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1158\/1078-0432.CCR-18-4147","article-title":"Radiotherapy eradicates malignant T cells and is associated with improved survival in early-stage mycosis fungoides","volume":"26","author":"O'Malley","year":"2020","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.retram.2023.103390_bib0052","doi-asserted-by":"crossref","first-page":"2806","DOI":"10.1080\/10428194.2019.1605068","article-title":"Clinical and neurophysiological serial assessments of brentuximab vedotin-associated peripheral neuropathy","volume":"60","author":"Mariotto","year":"2019","journal-title":"Leuk. Lymphoma"},{"issue":"3","key":"10.1016\/j.retram.2023.103390_bib0053","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1038\/leu.2011.237","article-title":"Regulatory T cells and immunodeficiency in mycosis fungoides and sezary syndrome","volume":"26","author":"Krejsgaard","year":"2012","journal-title":"Leukemia"},{"key":"10.1016\/j.retram.2023.103390_bib0054","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1038\/bmt.2011.201","article-title":"Allogeneic hematopoietic SCT for primary cutaneous T cell lymphomas","volume":"47","author":"Paralkar","year":"2012","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.retram.2023.103390_bib0055","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1007\/s00277-018-3275-z","article-title":"Allogeneic hematopoietic stem cell transplantation in Primary Cutaneous T Cell Lymphoma","volume":"97","author":"Cudillo","year":"2018","journal-title":"Ann Hematol"},{"key":"10.1016\/j.retram.2023.103390_bib0056","doi-asserted-by":"crossref","first-page":"3341","DOI":"10.1182\/blood-2018-99-119566","article-title":"Donor lymphocyte infusion for primary cutaneous T cell lymphomas:A study from the francophone society of bone marrow transplantation and cellular therapy (SFGM-TC) andthe french study group on cutaneous lymphomas (GFLEC)","volume":"132","author":"Faiz","year":"2018","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.retram.2023.103390_bib0057","doi-asserted-by":"crossref","first-page":"72","DOI":"10.2991\/chi.k.210529.001","article-title":"Allogeneic Stem Cell Transplantation with a Novel Reduced Intensity Conditioning Regimen for the Treatment of Patients with Primary Cutaneous T-cell Lymphomas","volume":"3","author":"Stamouli","year":"2021","journal-title":"Clin Hematol Int"},{"issue":"7","key":"10.1016\/j.retram.2023.103390_bib0058","doi-asserted-by":"crossref","DOI":"10.1016\/j.tranon.2021.101079","article-title":"Novel antigens of CAR T cell therapy: new roads; old destination","volume":"14","author":"Safarzadeh Kozani","year":"2021","journal-title":"Transl Oncol"},{"issue":"7","key":"10.1016\/j.retram.2023.103390_bib0059","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1158\/1535-7163.MCT-20-1089","article-title":"In like a lamb; out like a lion: marching CAR T cells toward enhanced efficacy in B-ALL","volume":"20","author":"Safarzadeh Kozani","year":"2021","journal-title":"Mol Cancer Ther"},{"issue":"11","key":"10.1016\/j.retram.2023.103390_bib0060","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1007\/s12032-020-01416-3","article-title":"Strategies for having a more effective and less toxic CAR T-cell therapy for acute lymphoblastic leukemia","volume":"37","author":"Hashem Boroojerdi","year":"2020","journal-title":"Med Oncol"},{"issue":"4","key":"10.1016\/j.retram.2023.103390_bib0061","first-page":"502","article-title":"A VHH-based anti-MUC1 chimeric antigen receptor for specific retargeting of human primary T cells to MUC1-positive cancer cells","volume":"22","author":"Rajabzadeh","year":"2021","journal-title":"Cell J"},{"issue":"4","key":"10.1016\/j.retram.2023.103390_bib0062","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1007\/s12185-012-1037-6","article-title":"A caspase 8-based suicide switch induces apoptosis in nanobody- directed chimeric receptor expressing T cells","volume":"95","author":"Khaleghi","year":"2012","journal-title":"Int J Hematol"},{"issue":"924","key":"10.1016\/j.retram.2023.103390_bib0063","article-title":"Strategies for Dodging the obstacles in CAR T cell therapy","volume":"11","author":"Safarzadeh Kozani","year":"2021","journal-title":"Front Oncol"},{"key":"10.1016\/j.retram.2023.103390_bib0064","doi-asserted-by":"crossref","DOI":"10.1016\/j.tranon.2022.101459","article-title":"Resistance against anti-CD19 and anti-BCMA CAR T cells: Recent advances and coping strategies","volume":"22","author":"Atilla","year":"2022","journal-title":"Transl Oncol"},{"issue":"7","key":"10.1016\/j.retram.2023.103390_bib0065","doi-asserted-by":"crossref","first-page":"1546","DOI":"10.1182\/blood.V77.7.1546.1546","article-title":"Stages of T-cell receptor protein expression in T-cell acute lymphoblastic leukemia","volume":"77","author":"Campana","year":"1991","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.retram.2023.103390_bib0066","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1182\/blood-2017-01-761320","article-title":"CD7-edited T cells expressing a CD7-specific CAR for the therapy of T-cell malignancies","volume":"130","author":"Gomes-Silva","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.retram.2023.103390_bib0067","doi-asserted-by":"crossref","first-page":"259","DOI":"10.3389\/fonc.2019.00259","article-title":"CAR-Based Approaches to Cutaneous T-Cell Lymphoma","volume":"9","author":"Scarf\u00f2","year":"2019","journal-title":"Front Oncol"},{"issue":"9","key":"10.1016\/j.retram.2023.103390_bib0068","doi-asserted-by":"crossref","first-page":"4320","DOI":"10.3390\/ijms22094320","article-title":"Pharmacologic Control of CAR T Cells","volume":"22","author":"Caulier","year":"2021","journal-title":"Int J Mol Sci"},{"issue":"1","key":"10.1016\/j.retram.2023.103390_bib0069","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1186\/s13045-019-0801-y","article-title":"Targeting T cell malignancies using CAR-based immunotherapy: challenges and potential solutions","volume":"12","author":"Fleischer","year":"2019","journal-title":"J Hematol Oncol"},{"issue":"10","key":"10.1016\/j.retram.2023.103390_bib0070","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1182\/blood-2018-03-837609","article-title":"Nonviral RNA chimeric antigen receptor-modified T cells in patients with Hodgkin lymphoma","volume":"132","author":"Svoboda","year":"2018","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.retram.2023.103390_bib0071","doi-asserted-by":"crossref","first-page":"1970","DOI":"10.1038\/s41375-018-0065-5","article-title":"An \u201coff-the-shelf\u201d fratricide-resistant CAR-T for the treatment of T cell hematologic malignancies","volume":"32","author":"Cooper","year":"2018","journal-title":"Leukemia"},{"issue":"10","key":"10.1016\/j.retram.2023.103390_bib0072","doi-asserted-by":"crossref","first-page":"2151","DOI":"10.1038\/leu.2017.8","article-title":"Preclinical targeting of aggressive T-cell malignancies using anti-CD5 chimeric antigen receptor","volume":"31","author":"Chen","year":"2017","journal-title":"Leukemia"},{"issue":"3","key":"10.1016\/j.retram.2023.103390_bib0073","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2017.1407898","article-title":"Development of chimeric antigen receptors targeting T-cell malignancies using two structurally different anti-CD5 antigen binding domains in NK and CRISPR-edited T cell lines","volume":"7","author":"Raikar","year":"2018","journal-title":"OncoImmunology"},{"issue":"9","key":"10.1016\/j.retram.2023.103390_bib0074","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.3390\/biomedicines9091201","article-title":"New Orders to an Old Soldier: Optimizing NK Cells for Adoptive Immunotherapy in Hematology","volume":"9","author":"Gunduz","year":"2021","journal-title":"Biomedicines"},{"issue":"6382","key":"10.1016\/j.retram.2023.103390_bib0075","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1126\/science.aar6711","article-title":"CAR T cell immunotherapy for human cancer","volume":"359","author":"June","year":"2018","journal-title":"Science"},{"issue":"3","key":"10.1016\/j.retram.2023.103390_bib0076","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1002\/cyto.b.21738","article-title":"Naive\/memory T-cell phenotypes in leukemic cutaneous T-cell lymphoma: Putative cell of origin overlaps disease classification","volume":"96","author":"Horna","year":"2019","journal-title":"Cytometry B Clin Cytom"},{"issue":"26","key":"10.1016\/j.retram.2023.103390_bib0077","doi-asserted-by":"crossref","first-page":"3732","DOI":"10.1182\/blood.2021014468","article-title":"Resistance to mogamulizumab is associated with loss of CCR4 in cutaneous Tcell lymphom","volume":"139","author":"Beygi","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.retram.2023.103390_bib0078","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.968395","article-title":"CAR-T cell development for Cutaneous T cell Lymphoma: current limitations and potential treatment strategies","volume":"13","author":"To","year":"2022","journal-title":"Front Immunol"},{"issue":"13","key":"10.1016\/j.retram.2023.103390_bib0079","doi-asserted-by":"crossref","first-page":"4537","DOI":"10.1182\/blood-2002-05-1525","article-title":"Human CD5 promotes B-cell survival through stimulation of autocrine IL-10 production","volume":"100","author":"Gary-Gouy","year":"2002","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.retram.2023.103390_bib0080","doi-asserted-by":"crossref","first-page":"4335","DOI":"10.4049\/jimmunol.179.7.4335","article-title":"Natural phosphorylation of CD5 in chronic lymphocytic leukemia B cells and analysis of CD5-regulated genes in a B cell line suggest a role for CD5 in malignant phenotype","volume":"179","author":"Gary-Gouy","year":"2007","journal-title":"J Immunol"},{"issue":"4","key":"10.1016\/j.retram.2023.103390_bib0081","doi-asserted-by":"crossref","first-page":"2903","DOI":"10.1128\/MCB.19.4.2903","article-title":"CD5 negatively regulates the T-cell antigen receptor signal transduction pathway: involvement of SH2-containing phosphotyrosine phosphatase SHP-1","volume":"19","author":"Perez-Villar","year":"1999","journal-title":"Mol Cell Biol"},{"issue":"3","key":"10.1016\/j.retram.2023.103390_bib0082","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1182\/blood.V68.3.752.752","article-title":"Monoclonal antibody T101 in T cell malignancies: a clinical, pharmacokinetic,and immunologic correlation","volume":"68","author":"Bertram","year":"1986","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.retram.2023.103390_bib0083","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1182\/blood-2015-02-629527","article-title":"A T-cell-directed chimeric antigen receptor for the selective treatment of T-cell malignancies","volume":"126","author":"Mamonkin","year":"2015","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.retram.2023.103390_bib0084","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1158\/2326-6066.CIR-17-0126","article-title":"Reversible transgene expression reduces fratricide and permits 4-1BB costimulation of CAR T cells directed to T-cell malignancies","volume":"6","author":"Mamonkin","year":"2018","journal-title":"Cancer Immunol Res"},{"key":"10.1016\/j.retram.2023.103390_bib0085","doi-asserted-by":"crossref","unstructured":"Rayne H. Rouce, LaQuisa C. Hill, Tyler S. Smith, Lina Yang, Blakely Boriskie, Madhuwanti Srinivasan, Huimin Zhang, Silvana Perconti, Birju Mehta, Olga Dakhova, Bambi J. Grilley, Helen E. Heslop, Malcolm K. Brenner, Maksim Mamonkin; Early Signals of Anti-Tumor Efficacy and Safety with Autologous CD5.CAR T-Cells in Patients with Refractory\/Relapsed T-Cell Lymphoma. Blood 2021; 138 (Supplement 1): 654.","DOI":"10.1182\/blood-2021-154142"},{"issue":"9","key":"10.1016\/j.retram.2023.103390_bib0086","doi-asserted-by":"crossref","first-page":"2707","DOI":"10.1016\/j.ymthe.2021.07.001","article-title":"The rational development of CD5-targeting biepitopic CARs with fully human heavy-chain-only antigen recognition domains","volume":"29","author":"Dai","year":"2021","journal-title":"Mol Ther"},{"key":"10.1016\/j.retram.2023.103390_bib0087","article-title":"Phase I study of donor-derived CD5 CAR T cells in patients with relapsed or refractory T-cell acute lymphoblastic leukemia","volume":"40","author":"Pan","year":"2022","journal-title":"Journal of Clinical Oncology"},{"key":"10.1016\/j.retram.2023.103390_bib0088","article-title":"CD5 knockout enhances the potency of multiplex base-edited allogeneic anti-CD5 CAR T-cell therapy for the treatment of T-cell malignancies","volume":"9","author":"Yang","year":"2021","journal-title":"Journal for ImmunoTherapy of Cancer"},{"issue":"4","key":"10.1016\/j.retram.2023.103390_bib0089","first-page":"331","article-title":"Structure and function of the CD7 molecule","volume":"19","author":"Sempowski","year":"1999","journal-title":"Crit Rev Immunol"},{"issue":"16","key":"10.1016\/j.retram.2023.103390_bib0090","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.149819","article-title":"CD7-deleted hematopoietic stem cells can restore immunity after CAR T cell therapy","volume":"6","author":"Kim","year":"2021","journal-title":"JCI Insight"},{"issue":"25","key":"10.1016\/j.retram.2023.103390_bib0091","doi-asserted-by":"crossref","first-page":"2348","DOI":"10.1182\/bloodadvances.2017009928","article-title":"Blockade of CD7 expression in T cells for effective chimeric antigen receptor targeting of T-cell malignancies","volume":"1","author":"Png","year":"2017","journal-title":"Blood Adv"},{"issue":"1","key":"10.1016\/j.retram.2023.103390_bib0092","first-page":"64","article-title":"A novel CD7 chimeric antigen receptor-modified NK-92MI cell line targeting T-cell acute lymphoblastic leukemia","volume":"9","author":"You","year":"2019","journal-title":"Am J Cancer Res"},{"key":"10.1016\/j.retram.2023.103390_bib0093","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1016\/j.omto.2022.02.013","article-title":"Feasibility study of a novel preparation strategy for anti-CD7 CAR-T cells with a recombinant anti-CD7 blocking antibody","volume":"24","author":"Ye","year":"2022","journal-title":"Mol Ther Oncolytics"},{"key":"10.1016\/j.retram.2023.103390_bib0094","article-title":"Feasibility and preclinical efficacy of CD7-unedited CD7 CAR T cells for T cell malignancies","author":"Watanabe","year":"2022","journal-title":"Mol Ther"},{"issue":"Supplement 1","key":"10.1016\/j.retram.2023.103390_bib0095","doi-asserted-by":"crossref","first-page":"1696","DOI":"10.1182\/blood-2021-149384","article-title":"Naturally Selected Anti-CD7 CAR-T Cells without Additional Genetic Manipulations As a Potentially Superior Therapy for T-Cell Malignancies","volume":"138","author":"Ying","year":"2021","journal-title":"Blood"},{"issue":"Supplement 1","key":"10.1016\/j.retram.2023.103390_bib0096","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1182\/blood-2021-147667","article-title":"High Effectiveness and Safety of Anti-CD7 CAR T-Cell Therapy in Treating Relapsed or Refractory (R\/R) T-Cell Acute Lymphoblastic Leukemia (T-ALL)","volume":"138","author":"Yang","year":"2021","journal-title":"Blood"},{"issue":"Supplement 1","key":"10.1016\/j.retram.2023.103390_bib0097","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1182\/blood-2021-147754","article-title":"A Novel and Successful Patient or Donor-Derived CD7-Targeted CAR T-Cell Therapy for Relapsed or Refractory T-Cell Lymphoblastic Lymphoma (R\/R T-LBL)","volume":"138","author":"Yang","year":"2021","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.retram.2023.103390_bib0098","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1097\/01.HS9.0000843852.28463.2a","article-title":"CD7 Chimeric Antigen Receptor T Cells Bridging to Allogeneic Hematopoietic Stem Cell Transplantation Improved Disease-Free Survival in Refractory\/Relapsed T-Cell Acute Lymphoblastic Leukemia","author":"Li","year":"2022","journal-title":"HemaSphere"},{"key":"10.1016\/j.retram.2023.103390_bib0099","doi-asserted-by":"crossref","first-page":"3829","DOI":"10.1182\/blood-2021-149999","article-title":"A Single-Arm, Open-Label, Pilot Trial of Autologous CD7-CAR-T Cells for CD7 Positive Relapsed and Refractory T-Lymphoblastic Leukemia\/Lymphoma","volume":"138","author":"Zhang","year":"2021","journal-title":"Blood"},{"issue":"13","key":"10.1016\/j.retram.2023.103390_bib0100","doi-asserted-by":"crossref","first-page":"2830","DOI":"10.1158\/1078-0432.CCR-21-4097","article-title":"Autologous Nanobody-Derived Fratricide-Resistant CD7-CAR T-cell Therapy for Patients with Relapsed and Refractory T-cell Acute Lymphoblastic Leukemia\/Lymphoma","volume":"28","author":"Zhang","year":"2022","journal-title":"Clin Cancer Res"},{"issue":"30","key":"10.1016\/j.retram.2023.103390_bib0101","doi-asserted-by":"crossref","first-page":"3340","DOI":"10.1200\/JCO.21.00389","article-title":"Donor-Derived CD7 Chimeric Antigen Receptor T Cells for T-Cell Acute Lymphoblastic Leukemia: First-in-Human, Phase I Trial","volume":"39","author":"Pan","year":"2021","journal-title":"Journal of Clinical Oncology"},{"key":"10.1016\/j.retram.2023.103390_bib0102","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1038\/s41422-022-00721-y","article-title":"Genetically modified CD7-targeting allogeneic CAR-T cell therapy with enhanced efficacy for relapsed\/refractory CD7-positive hematological malignancies: a phase I clinical study","volume":"32","author":"Hu","year":"2022","journal-title":"Cell Res"},{"issue":"12","key":"10.1016\/j.retram.2023.103390_bib0103","doi-asserted-by":"crossref","first-page":"1860","DOI":"10.1097\/PAS.0b013e3181bf677d","article-title":"CD30 expression and proliferative fraction in nontransformed mycosis fungoides","volume":"33","author":"Edinger","year":"2009","journal-title":"Am J Surg Pathol"},{"issue":"10094","key":"10.1016\/j.retram.2023.103390_bib0104","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1016\/S0140-6736(17)31266-7","article-title":"ALCANZA study group. Brentuximab vedotin or physician's choice in CD30-positive cutaneous T-cell lymphoma (ALCANZA): an international, open-label, randomised, phase 3, multicentre trial","volume":"390","author":"Prince","year":"2017","journal-title":"Lancet"},{"issue":"9","key":"10.1016\/j.retram.2023.103390_bib0105","doi-asserted-by":"crossref","first-page":"3462","DOI":"10.1172\/JCI94306","article-title":"Clinical and immunological responses after CD30-specific chimeric antigen receptor-redirected lymphocytes","volume":"127","author":"Ramos","year":"2017","journal-title":"J Clin Investig"},{"issue":"32","key":"10.1016\/j.retram.2023.103390_bib0106","doi-asserted-by":"crossref","first-page":"3794","DOI":"10.1200\/JCO.20.01342","article-title":"Anti-CD30 CAR-T Cell Therapy in Relapsed and Refractory Hodgkin Lymphoma","volume":"38","author":"Ramos","year":"2020","journal-title":"J Clin Oncol"},{"issue":"8","key":"10.1016\/j.retram.2023.103390_bib0107","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1038\/mt.2016.82","article-title":"Superior therapeutic index in lymphoma therapy: CD30+ CD34+ hematopoietic stem cells resist a chimeric antigen receptor T-cell attack","volume":"24","author":"Hombach","year":"2016","journal-title":"Mol Ther"},{"key":"10.1016\/j.retram.2023.103390_bib0108","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1182\/blood-2021-154142","article-title":"Early Signals of Anti-Tumor Efficacy and Safety with Autologous CD5.CAR T-Cells in Patients with Refractory\/Relapsed T-Cell Lymphoma","volume":"138","author":"Rouce","year":"2021","journal-title":"Blood"},{"issue":"49","key":"10.1016\/j.retram.2023.103390_bib0109","doi-asserted-by":"crossref","first-page":"17576","DOI":"10.1073\/pnas.1420936111","article-title":"Molecular architecture of the \u03b1\u03b2 T cell receptor-CD3 complex","volume":"111","author":"Birnbaum","year":"2014","journal-title":"Proc Natl Acad Sci"},{"issue":"13","key":"10.1016\/j.retram.2023.103390_bib0110","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.99442","article-title":"TCR\u03b1\u03b2\/CD3 disruption enables CD3-specific antileukemic T cell immunotherapy","volume":"3","author":"Rasaiyaah","year":"2018","journal-title":"JCI Insight"},{"issue":"35","key":"10.1016\/j.retram.2023.103390_bib0111","doi-asserted-by":"crossref","first-page":"56219","DOI":"10.18632\/oncotarget.11019","article-title":"Novel anti-CD3 chimeric antigen receptor targeting of aggressive T cell malignancies","volume":"7","author":"Chen","year":"2016","journal-title":"Oncotarget"},{"issue":"2","key":"10.1016\/j.retram.2023.103390_bib0112","doi-asserted-by":"crossref","first-page":"104","DOI":"10.2174\/138945009787354539","article-title":"Anti-CD3 recombinant diphtheria immunotoxin therapy of cutaneous T cell lymphoma","volume":"10","author":"Frankel","year":"2009","journal-title":"Curr Drug Targets"},{"issue":"6","key":"10.1016\/j.retram.2023.103390_bib0113","doi-asserted-by":"crossref","first-page":"794","DOI":"10.3324\/haematol.2015.123711","article-title":"Resimmune, an anti-CD3\u03b5 recombinant immunotoxin, induces durable remissions in patients with cutaneous T-cell lymphoma","volume":"100","author":"Frankel","year":"2015","journal-title":"Haematologica"},{"issue":"3","key":"10.1016\/j.retram.2023.103390_bib0114","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1038\/leu.2015.311","article-title":"Preclinical targeting of human T-cell malignancies using CD4-specific chimeric antigen receptor (CAR)-engineered T cells","volume":"30","author":"Pinz","year":"2016","journal-title":"Leukemia"},{"issue":"3","key":"10.1016\/j.retram.2023.103390_bib0115","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1007\/s12015-019-09876-5","article-title":"Targeting T cell malignancies using CD4CAR T-cells and implementing a natural safety switch","volume":"15","author":"Ma","year":"2019","journal-title":"Stem Cell Rev Rep"},{"issue":"14","key":"10.1016\/j.retram.2023.103390_bib0116","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1182\/blood-2018-04-842708","article-title":"Anti-CD37 chimeric antigen receptor T cells are active against b- and T-celllymphomas","volume":"132","author":"Scarfo","year":"2018","journal-title":"Blood"},{"issue":"S2","key":"10.1016\/j.retram.2023.103390_bib0117","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1002\/hon.2437_32","article-title":"A phase 1 study of the anti-CD37 antibody-drug conjugate AGS67E in advanced lymphoid malignancies. Interim Results","volume":"35","author":"Sawas","year":"2017","journal-title":"Hematol Oncol"},{"issue":"22","key":"10.1016\/j.retram.2023.103390_bib0118","doi-asserted-by":"crossref","first-page":"3591","DOI":"10.3390\/cells11223591","article-title":"Targeting the CD47-SIRP\u03b1 Axis: Present Therapies and the Future for Cutaneous T-cell Lymphoma","volume":"11","author":"Xiao","year":"2022","journal-title":"Cells"},{"issue":"12","key":"10.1016\/j.retram.2023.103390_bib0119","doi-asserted-by":"crossref","first-page":"3243","DOI":"10.1016\/j.jid.2022.06.016","article-title":"Cutaneous Lymphocyte Antigen Is a Potential Therapeutic Target in Cutaneous T-Cell Lymphoma","volume":"142","author":"Peru","year":"2022","journal-title":"J Invest Dermatol"},{"issue":"1","key":"10.1016\/j.retram.2023.103390_bib0120","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1182\/blood.2021013648","article-title":"Anti-CCR9 chimeric antigen receptor T cells for T-cell acute lymphoblastic leukemia","volume":"140","author":"Maciocia","year":"2022","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.retram.2023.103390_bib0121","doi-asserted-by":"crossref","first-page":"3466","DOI":"10.1038\/s41375-021-01282-6","article-title":"Base-edited CAR T cells for combinational therapy against T cell malignancies","volume":"35","author":"Georgiadis","year":"2021","journal-title":"Leukemia"},{"issue":"1","key":"10.1016\/j.retram.2023.103390_bib0122","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1038\/s41392-022-00898-z","article-title":"T cells expressing CD5\/CD7 bispecific chimeric antigen receptors with fully human heavy-chain-only domains mitigate tumor antigen escape","volume":"7","author":"Dai","year":"2022","journal-title":"Signal Transduct Target Ther"},{"issue":"2","key":"10.1016\/j.retram.2023.103390_bib0123","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1158\/1078-0432.CCR-14-0830","article-title":"Reduction of regulatory T cells by mogamulizumab, a defucosylated anti-CChemokine receptor 4 antibody, in patients with aggressive\/refractory mycosis fungoides and sezary syndrome","volume":"21","author":"Ni","year":"2015","journal-title":"Clin Cancer Res"},{"issue":"11","key":"10.1016\/j.retram.2023.103390_bib0124","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1200\/JCO.2013.52.0924","article-title":"Multicenter phase II study of mogamulizumab (KW-0761), a defucosylated anti-ccchemokine receptor 4 antibody, in patients with relapsed peripheral T-celllymphoma and cutaneous T-cell lymphoma","volume":"32","author":"Ogura","year":"2014","journal-title":"J Clin Oncol"},{"issue":"25","key":"10.1016\/j.retram.2023.103390_bib0125","doi-asserted-by":"crossref","first-page":"6392","DOI":"10.1182\/blood-2009-03-209650","article-title":"et alT lymphocytes coexpressing CCR4 and a chimeric antigen receptor targeting CD30 have improved homing and antitumor activity in a Hodgkin tumor model","volume":"113","author":"Di Stasi","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.retram.2023.103390_bib0126","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1182\/blood-2021-148102","article-title":"CD30-Directed CAR-T Cells Co-Expressing CCR4 in Relapsed\/Refractory Hodgkin Lymphoma and CD30+ Cutaneous T Cell Lymphoma","volume":"138","author":"Grover","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.retram.2023.103390_bib0127","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1097\/01.HS9.0000843940.96598.e2","article-title":"S262: The Cobalt-Lym Study of CTX130: A Phase 1 Dose Escalation Study of CD70-Targeted Allogeneic Crispr-CAS9-Engineered Car T Cells in Patients with Relapsed\/Refractory (R\/R) T-Cell Malignan-Cies","volume":"6","author":"Iyer","year":"2022","journal-title":"Hemasphere"}],"container-title":["Current Research in Translational Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2452318623000144?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2452318623000144?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T00:40:30Z","timestamp":1762821630000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2452318623000144"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4]]},"references-count":127,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023,4]]}},"alternative-id":["S2452318623000144"],"URL":"https:\/\/doi.org\/10.1016\/j.retram.2023.103390","relation":{},"ISSN":["2452-3186"],"issn-type":[{"value":"2452-3186","type":"print"}],"subject":[],"published":{"date-parts":[[2023,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Are we there yet? cellular therapies for cutaneous T cell lymphoma","name":"articletitle","label":"Article Title"},{"value":"Current Research in Translational Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.retram.2023.103390","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"103390"}}